TO THE EDITOR
A new SRC-Abl dual inhibitor, BMS354825, has recently been presented as a possible tool to overcome resistance to imatinib in neoplasias caused by oncogenic variants of the tyrosine kinase domain of Bcr-Abl.
1 BMS354825 is able to inhibit in vitro and in vivo 14 of 15 imatinib-resistant Bcr-Abl mutants, while the T315I was clearly resistant to the compound. 1 It has been suggested that BMS354825 could fit into a conformation of Abl different from the inactive one (ie the one that imatinib preferentially binds). 1 To better understand imatinib and BMS354825 binding, the two molecules were docked using the FLEXX software 2 in different available structures of Abl: 1IEP Abl (closed conformation) in which the activation loop is closed, and 1M52 Abl (intermediate conformation) where the activation loop is open.
3
In both structures, the highly conserved DFG motif has a similar conformation, with the phenylalanine residue pointing towards the ATP binding site, while the aspartic acid residue points away from it (Figure 1a) , indicating that the enzyme is still in its inactive form, that is, the one unable to perform the catalytic reaction. Furthermore, a model of Abl with the DFG in the productive conformation, with the aspartic acid residue pointing towards the ATP binding pocket and the activation loop in the open conformation (similar to those seen in the 1IR3 conformation 4 and in the human lympocyte kinase structure 3LCK 5 ), was generated (open conformation) to study the effect of its orientation on the binding mode of these compounds. The used docking protocol allowed us to reproduce accurately the available binding orientations of imatinib and PD173955, as previously determined on crystal structures.
As shown in Figure 1a and b, BMS354825 binds, at difference with imatinib, both conformations of Abl, although in an opposite orientation. In fact, while the piperazine moiety of BMS354825 is aligned to the one of imatinib in the closed conformation (Figure 1a (Figure 1a ), it adopts a bended one in the active conformation Abl model. This bending of the molecule is similar to the one seen for imatinib in the human spleen tyrosine kinase (1XBB). 6 Noteworthy is the fact that the IC 50 value of imatinib for the human spleen tyrosine kinase is in the micromolar range. 6 The binding mode predicted for BMS354825 in the open conformation of Abl does not allow tight binding to the protein and a micromolar IC 50 value could be expected for this conformation, in contrast to the experimentally determined nanomolar IC 50 values.
1 This suggests that the putative binding mode of BMS35425 in the active conformation should not be the pharmacologically relevant one. On the contrary, the snug fit and hydrogen bond pattern of observed with the closed and intermediate conformations of the protein (Figure 1a) can explain the nanomolar IC 50 values of BMS354825.
Taken together, our docking results suggest that the active conformation of Abl is not favorable for the binding of BMS354825. This is mainly due to the fact that the conformation of the aspartic acid residue of the DFG motif substantially changes the electrostatic characteristics of the ATP binding pocket. Furthermore, Figure 1 shows that BMS354825 closely interacts with T315, which can either form a hydrogen bond to the nitrogen or the oxygen of the amide group of the BMS354825 compound (in Figure 1b , the hydrogen bond to the oxygen is shown). It is in fact known that residue 315 of Abl is not required for ATP binding as indicated by previously published data on ATP affinity. 7 The refractoriness of the T315I mutant of BCR/ABL to BMS354825 further indicates that this compound indeed binds to the inactive form of Abl, as imatinib does, although requiring a lower conformational stringency, with the ability of binding more intermediate conformations than imatinib. These findings provide further evidence that BMS354825 cannot strictly be defined as true ATP-competitive inhibitor as indicated by Shah et al.
1 Considering the fact that BMS354825 inhibits several Abl mutants and that the intermediate conformation of Abl is less restrictive than the closed one, the binding mode depicted in the intermediate conformation might be the pharmacologically relevant one. It remains to be established whether the 2-log difference in potency between BMS354825 and imatinib is entirely due to the lower stringency of BMS354825, or to a possible higher rigidity of it. Spotlight Correspondence
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